Research reveals that the fibrocystin C-terminal domain inhibits Src/STAT3 signaling, which is linked to cystogenesis in kidney epithelial cells. This discovery could provide insights into therapeutic strategies for kidney diseases.

Recent research highlights the importance of kidney biopsies in accurately diagnosing kidney conditions in diabetes patients. This study aims to reduce mislabeling and improve patient outcomes by providing clearer insights into kidney pathology.

Recent research highlights the use of cell-type-specific damage scores to track disease trajectories in kidney and liver diseases through single-cell and spatial transcriptomics. This innovative approach could enhance understanding of disease progression and inform future therapeutic strategies.

Boulevard Bio has launched with $65 million in funding from Deerfield Management to develop multi-specific antibody programs targeting autoimmune diseases. The New York-based biotech aims to improve treatment for kidney disease and enhance precision immunology.

Securing funding from such a high-caliber syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD. This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare ... Securing funding from such a high-caliber syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD. This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases.” Paul Callaghan, Investment Director, Scottish National Investment Bank: “Our investment in Mironid reflects our commitment to backing impactful Scottish businesses with high-growth potential. Mironid exemplifies Scotland’s growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease. Scottish National Investment Bank joins existing investors Roche Venture Fund, Epidarex Capital, Sofinnova Partners and BioGeneration Ventures · Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces it has raised $46 million in a Series B funding round. Preclinical data shows significant efficacy and a favourable safety profile across all disease endpoints, including a reduction in cyst number and kidney volume. The ability of cAMP modulators to prevent new cyst formation and arrest the growth of existing cysts is indicative of the potential to offer an effective and durable treatment option with an improved side-effect profile for all ADPKD patients. The funding round was supported by new investor the Scottish National Investment Bank and existing investors the Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde.